To address this issue, we designed and performed the current study comparing survival of three subgroups of NPM1 mutated AML: group A, without MDS-related gene mutations; group B, with FLT3-ITD mutation regardless of AR; and group C, with MDS-related gene mutations. Here, NPM1 is linked to acute myeloid leukemia.